Snapshot

The INVIMA Abbreviated Procedure (Article 27) pathway has been developed by the Instituto Nacional de Vigilancia de Medicamentos y Alimentos of Colombia.

It is an abridged review (a reliance pathway).

When relevant, the agency relies on prior decisions from Argentina Australia Brazil Canada Chile Denmark France Germany Israel Japan Mexico Netherlands New Zealand Norway South Korea Sweden Switzerland Turkey United Kingdom United States

The official timeline for approval is about 90 days. In practice, INVIMA takes more time than the legally established limits. The INVIMA takes approximately eight to 17 months to grant an MA for medicinal products already included in the Pharmacological Code.